ERBB2 and breast carcinoma: Since the drug regimen for breast cancer patients is highly determined by the tumor molecular subtype, we next analyzed the correlation between high NSMCE2 gene expression levels with response to chemotherapy for each ER + PR + , HER2 + or TN tumor subtypes.